Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

Single-cell transcriptomics has revolutionized the study of cellular diversity and function by enabling gene expression ...

This comes on the heels of Parse invalidating the patents that 10x Genomics had asserted against Parse's Evercode Whole Transcriptome products and the subsequent cancellation of a trial on those ...

From AI-driven tools to new applications, Epic continues to help healthcare organizations advance in a rapidly changing environment. VERONA, Wis., March 4, 2025 /PRNewswire/ -- At the 2025 HIMSS ...

For 2025, 10X Genomics expects revenue to range between $610 million and $630 million, representing 0-3% growth. The company anticipates double-digit growth in Chromium reactions and spatial revenue, ...

1. AI-Driven Genomics For Precision Medicine AI has revolutionized genomic medicine, paving the way for rapid advancements in precision medicine, a key focus for the future. Cancer is recognized ...

The certified compatibility is between 10x Genomics’ latest Chromium Universal GEM-X 3’ and GEM-X 5’ single-cell chemistries — which enhance sensitivity while reducing cost per cell — and Oxford ...